Christiane Marth
#141,011
Most Influential Person Now
Christiane Marth's AcademicInfluence.com Rankings
Christiane Marthphilosophy Degrees
Philosophy
#7360
World Rank
#10564
Historical Rank
Logic
#4416
World Rank
#5705
Historical Rank
Download Badge
Philosophy
Christiane Marth's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Biomedical Sciences University of California, San Francisco
Why Is Christiane Marth Influential?
(Suggest an Edit or Addition)Christiane Marth's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) (1582)
- A pooled analysis of bone marrow micrometastasis in breast cancer. (2005) (1290)
- Epigenetic stem cell signature in cancer (2007) (1102)
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. (2015) (888)
- Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. (2010) (788)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020) (559)
- The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer (2005) (531)
- FBXW7/hCDC4 is a general tumor suppressor in human cancer. (2007) (473)
- Endocrine therapy plus zoledronic acid in premenopausal breast cancer. (2009) (425)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (417)
- Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial (2015) (405)
- Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease (1999) (374)
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference (2011) (372)
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015) (351)
- Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. (2008) (339)
- DNA methylation in serum of breast cancer patients: an independent prognostic marker. (2003) (335)
- Incorporation of pazopanib in maintenance therapy of ovarian cancer. (2014) (304)
- Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen (2004) (290)
- Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. (2000) (290)
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (2019) (287)
- Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. (1996) (276)
- hCDC4 gene mutations in endometrial cancer. (2002) (272)
- DNA Hypomethylation and Ovarian Cancer Biology (2004) (265)
- Genomic index of sensitivity to endocrine therapy for breast cancer. (2010) (257)
- Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. (2005) (248)
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. (2014) (236)
- A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation (2006) (233)
- Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial (2000) (222)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (208)
- Why did p53 gene therapy fail in ovarian cancer? (2003) (201)
- Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. (2006) (200)
- Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. (2011) (200)
- Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. (2003) (197)
- Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer (2008) (195)
- L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. (2013) (195)
- Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. (1997) (179)
- Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. (2006) (178)
- Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. (2006) (178)
- International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). (2012) (159)
- Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo (2004) (155)
- ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015) (151)
- DNA Methylation in Serum and Tumors of Cervical Cancer Patients (2004) (133)
- Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (132)
- Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. (2002) (127)
- Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients (2012) (126)
- Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. (2004) (121)
- Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. (2009) (119)
- Clinical Relevance of E2F Family Members in Ovarian Cancer—An Evaluation in a Training Set of 77 Patients (2007) (118)
- Mammaglobin Gene Expression: A Superior Marker of Breast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptor and Cytokeratin-19 (2000) (117)
- Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. (1996) (115)
- Methylated DNA collected by tampons--a new tool to detect endometrial cancer. (2004) (114)
- Pregnancies after Adjustable Gastric Banding (2001) (114)
- Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications (2015) (113)
- Up‐regulation of L1CAM is linked to loss of hormone receptors and E‐cadherin in aggressive subtypes of endometrial carcinomas (2010) (111)
- Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo (2005) (110)
- CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients (2004) (100)
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (2017) (98)
- European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery (2016) (96)
- Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. (2008) (96)
- Expression of 7F7‐antigen, a human adhesion molecule identical to intercellular adhesion molecule‐1 (ICAM‐1) in human carcinomas and their stromal fibroblasts (1989) (92)
- HE4 is an independent prognostic marker in endometrial cancer patients. (2012) (92)
- European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery (2017) (92)
- Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis (2002) (90)
- Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. (1986) (90)
- LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. (2017) (88)
- Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. (2003) (87)
- Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. (1996) (86)
- Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup (2014) (86)
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. (2016) (84)
- Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. (1985) (81)
- Analysis of Aberrant DNA Methylation and Human Papillomavirus DNA in Cervicovaginal Specimens to Detect Invasive Cervical Cancer and Its Precursors (2004) (80)
- Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. (1998) (79)
- Expression of the E2F Family of Transcription Factors and Its Clinical Relevance in Ovarian Cancer (2006) (79)
- Alternative splicing of p53 and p73: the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer (2010) (79)
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
- Epigenetic Downregulation of the Retinoic Acid Receptor-β2 Gene in Breast Cancer (2001) (78)
- Nomogram prediction for overall survival of patients diagnosed with cervical cancer (2012) (77)
- Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. (2008) (76)
- Interferon-γ expression is an independent prognostic factor in ovarian cancer (2004) (73)
- Favorable prognostic value of SOCS2 and IGF-I in breast cancer (2007) (73)
- Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. (1985) (72)
- Significance of thrombocytosis in patients with epithelial ovarian cancer (1994) (70)
- BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer (2018) (69)
- Relationship between quantity of silver stained nucleolar organizer regions associated proteins (Ag-NORs) and population doubling time in ten breast cancer cell lines. (1992) (69)
- Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. (2004) (67)
- MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status (2003) (66)
- Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients (2011) (64)
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (2015) (64)
- Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer (2016) (64)
- Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. (1984) (62)
- Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. (1999) (61)
- Interferon‐gamma in combination with carboplatin and paclitaxel as a safe and effective first‐line treatment option for advanced ovarian cancer: results of a phase I/II study (2006) (61)
- Genome-Scale Screen for DNA Methylation-Based Detection Markers for Ovarian Cancer (2011) (59)
- Tamoxifen in the treatment of recurrent ovarian carcinoma. (2000) (59)
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (59)
- Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor (2001) (58)
- Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma (2000) (57)
- Cyclin E dysregulation and chromosomal instability in endometrial cancer (2004) (57)
- Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy (2016) (56)
- Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. (1993) (55)
- Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. (1997) (55)
- Interferon-gamma expression is an independent prognostic factor in ovarian cancer. (2004) (54)
- Circulating tumor cells in metastatic breast cancer--toward individualized treatment? (2004) (54)
- Antiproliferative activity and apoptosis induced by retinoic acid receptor-gamma selectively binding retinoids in neuroblastoma. (1998) (53)
- Prognostic value of CD44 splice variant expression in ovarian cancer. (1995) (53)
- Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. (1997) (53)
- Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. (2016) (52)
- Ovarian cancer stem cells. (2012) (52)
- Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas (2002) (52)
- Different effects of interferons, interleukin‐1β and tumor necrosis factor‐α in normal (OSE) and malignant human ovarian epithelial cells (1996) (51)
- Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions. (2004) (51)
- Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. (1990) (50)
- The impact of risk factors and more stringent diagnostic criteria of gestational diabetes on outcomes in central European women. (2008) (50)
- Mammaglobin Expression in Gynecologic Malignancies and Malignant Effusions Detected by Nested Reverse Transcriptase-Polymerase Chain Reaction (2002) (50)
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). (2016) (50)
- Influence of Department Volume on Survival for Ovarian Cancer: Results From a Prospective Quality Assurance Program of the Austrian Association for Gynecologic Oncology (2009) (49)
- Peritoneum and Tissues of the Female Reproductive Tract as Physiological Sources of CA-125 (1998) (49)
- Effect of retinoic acid and 4-hydroxytamoxifen on human breast cancer cell lines. (1984) (49)
- Free alpha-subunit, free beta-subunit of human chorionic gonadotropin (hCG), and intact hCG in sera of healthy individuals and testicular cancer patients. (1992) (49)
- Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD (2012) (48)
- Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. (2003) (47)
- DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. (2011) (47)
- Effects of Retinoic Acid and γ-Interferon on Expression of Retinoic Acid Receptor and Cellular Retinoic Acid-binding Protein in Breast Cancer Cells (1995) (46)
- S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer. (2011) (46)
- Ovarian cancer specific kallikrein profile in effusions. (2007) (46)
- Transforming growth factor-beta and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. (1990) (46)
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum (2020) (46)
- Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance (2015) (45)
- Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial (2012) (45)
- Modulation of Ovarian Carcinoma Tumor Marker CA-125 by γ-Interferon (1989) (45)
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial (2014) (45)
- Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. (1985) (45)
- Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. (2017) (44)
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma (2021) (43)
- Dual-energy contrast-enhanced spectral mammography (CESM) (2015) (43)
- Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma (2007) (43)
- Abstract S2-02: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial (2016) (43)
- Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. (2019) (43)
- Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. (2000) (42)
- Post-traumatic Stress Disorder Post Partum: The Impact of Birth on the Prevalence of Post-traumatic Stress Disorder (PTSD) in Multiparous Women. (2012) (42)
- Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer (2011) (42)
- Hopes and failures in front-line ovarian cancer therapy. (2019) (41)
- Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment (2010) (41)
- Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer (2011) (41)
- Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. (2004) (39)
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer (2011) (39)
- The N-Terminally Truncated p53 Isoform &Dgr;40p53 Influences Prognosis in Mucinous Ovarian Cancer (2012) (39)
- Circulating immunostimulatory protein 90K and soluble interleukin‐2‐receptor in human ovarian cancer (1996) (38)
- E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. (2010) (38)
- Corrections to "Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2018) (38)
- Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. (2001) (38)
- Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. (2000) (38)
- Effects of biological response modifiers on ovarian carcinoma cell lines. (1989) (37)
- New insights into p53 regulation and gene therapy for cancer. (2000) (37)
- The Prognostic Impact of Bone Marrow Micrometastases in Women with Breast Cancer (2009) (36)
- Front-line therapy of advanced epithelial ovarian cancer: standard treatment (2017) (35)
- Surgical and systemic management of endometrial cancer: an international survey (2015) (34)
- Intratumoral interferon regulatory factor (IRF)‐1 but not IRF‐2 is of relevance in predicting patient outcome in ovarian cancer (2009) (34)
- Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer (2007) (33)
- Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. (2009) (33)
- High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. (1997) (33)
- Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients. (2014) (32)
- Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer. (2011) (32)
- Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective (2020) (32)
- Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer (2011) (32)
- The effect of EUSOMA certification on quality of breast cancer care. (2015) (31)
- European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies (2010) (31)
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2022) (31)
- Adherence evaluation of endocrine treatment in breast cancer: methodological aspects (2012) (31)
- Anaphylactic reaction to ampicillin and severe complication in the fetus (1991) (30)
- Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells. (1997) (30)
- Effects of interferons on the expression of the proto‐oncogene her‐2 in human ovarian carcinoma cells (1992) (30)
- Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. (2006) (30)
- High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome (2019) (29)
- Correlation of biochemical (receptors, endogenous tissue hormones) and quantitative morphologic (stereologic) findings in normal and hyperplastic human prostates. (1987) (29)
- Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. (2006) (29)
- Immunocytochemical versus biochemical receptor determination in normal and tumorous tissues of the female reproductive tract and the breast (1994) (29)
- The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study (2016) (28)
- Activity of retinoic acid receptor‐γ selectively binding retinoids alone and in combination with interferon‐γ in breast cancer cell lines (1997) (28)
- Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. (2018) (28)
- Precancerous Lesions of the Cervix, Vulva and Vagina According to the 2014 WHO Classification of Tumors of the Female Genital Tract (2015) (27)
- BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer (2018) (27)
- Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group. (2006) (27)
- Front-line therapy of advanced epithelial ovarian cancer: standard treatment. (2017) (27)
- Evidence for cosmetics as a source of mineral oil contamination in women. (2011) (27)
- Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma. (2008) (27)
- Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions (2007) (27)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. (2021) (27)
- Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. (2004) (27)
- Conservative management of abnormally invasive placenta: four case reports (2013) (27)
- Effects of retinoids and interferon‐gamma on cultured breast cancer cells in comparison with tumor necrosis factor alpha (1987) (27)
- Breast cancer in women: evaluation of benign and malignant axillary lymph nodes with contrast-enhanced ultrasound. (2010) (27)
- Immunotherapy in ovarian cancer: fake news or the real deal? (2019) (27)
- Correlation between steroid hormone receptors, histological and clinical parameters in ovarian carcinoma. (1988) (26)
- Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. (2002) (26)
- Vascular endothelial growth factor in serum and in the follicular fluid of patients undergoing hormonal stimulation for in-vitro fertilization. (1998) (26)
- The miR-34 family and its clinical significance in ovarian cancer (2020) (26)
- Effects of type‐I and ‐II interferons on 90K antigen expression in ovarian carcinoma cells (1994) (25)
- DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. (2004) (25)
- A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. (2004) (24)
- The prognostic value of nuclear roundness and neopterin in ovarian cancer. (1993) (24)
- Lead uptake by Picea abies seedlings: Effects of nitrogen source and mycorrhizas (1998) (24)
- Tamoxifen in the Treatment of Recurrent Ovarian Carcinoma (1997) (23)
- Role of forkhead box protein 3 expression in invasive breast cancer. (2007) (22)
- Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells. (1992) (22)
- Pooled Analysis of the Prognostic Relevance of Disseminated Tumor Cells in the Bone Marrow of Patients With Ovarian Cancer (2013) (22)
- Mechanism of synergistic action of all-trans- or 9-cis-retinoic acid and interferons in breast cancer cells (1993) (22)
- Ovarian Cancer Stem Cell Heterogeneity. (2019) (21)
- Epidermal growth factor reduces HER‐2 protein level in human ovarian carcinoma cells (1992) (21)
- Evaluation of bone marrow in breast cancer patients: prediction of clinical outcome and response to therapy. (2003) (21)
- The Influence of Atracurium, Cisatracurium, and Mivacurium on the Proliferation of Two Human Cell Lines In Vitro (2001) (20)
- Migrants and obstetrics in Austria—applying a new questionnaire shows differences in obstetric care and outcome (2013) (20)
- Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity (2009) (20)
- Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. (2009) (20)
- DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. (2019) (20)
- Sentinel node detection with the blue dye technique in early cervical cancer. (2006) (20)
- Inhibition of the estradiol-induced growth of cultured human breast cancer cells by the anti-estrogens tamoxifen, desmethyl-tamoxifen, 4-hydroxy-tamoxifen and enclomiphene. (1984) (20)
- Role of pertuzumab in the treatment of HER2-positive breast cancer. (2012) (19)
- Regulation of CA 125 Expression in Cultured Human Carcinoma Cells (1998) (19)
- Ovarian preservation in the surgical treatment of cervical carcinoma. (1999) (19)
- Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. (2020) (19)
- PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. (2016) (19)
- Vitamin A status and retinoid-binding proteins in carcinomas of the head and neck region. (1983) (18)
- Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study (2013) (18)
- Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial (2013) (18)
- Congenital Fibrosarcoma as Cause for Fetal Anemia: Prenatal Diagnosis and in utero Treatment (2008) (18)
- Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-γ and EGF (2006) (17)
- Fulminant course of a microinvasive vulvar carcinoma in an immunosuppressed woman. (1997) (17)
- High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer. (2010) (17)
- Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro (1999) (17)
- Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (2016) (16)
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015 (2015) (16)
- Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. (2008) (16)
- Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. (2008) (16)
- Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. (1996) (16)
- Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer (2013) (16)
- Different patterns of inducible nitric oxide synthase gene expression in ovarian carcinoma cell lines. (2000) (16)
- Effects of Taxol on choriocarcinoma cells. (1995) (16)
- Anaphylactic reaction to latex during cesarean delivery. (1996) (16)
- Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 (2021) (16)
- Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab. (2007) (15)
- Interaction of retinoic acid and interferon-alpha in breast cancer cell lines. (1996) (15)
- Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer (2020) (15)
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. (2022) (15)
- Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria (2016) (14)
- Genetic analyses in a variant of Mayer-Rokitansky-Kuster-Hauser syndrome (MURCS association) (2008) (14)
- ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab. (2018) (14)
- AGO Austria recommendations for genetic testing of patients with ovarian cancer (2015) (14)
- Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening (2010) (14)
- The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German “Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)”, the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology (2018) (13)
- 4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24) (2009) (13)
- Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? (2009) (13)
- Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial. (2010) (13)
- Ultrasound-guided core needle biopsy of the breast: does frozen section give an accurate diagnosis? (2007) (13)
- Interactions of Human Peritoneal Mesothelial Cells With Serous Ovarian Cancer Cell Spheroids—Evidence for a Mechanical and Paracrine Barrier Function of the Peritoneal Mesothelium (2014) (13)
- 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum (2019) (13)
- Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium (2019) (13)
- The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective (2021) (13)
- Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. (1996) (13)
- Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer. (2010) (13)
- Photodynamic therapy for recurrent gynecologic malignancy: a report on 4 cases (1999) (13)
- Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers (2016) (13)
- Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells. (1997) (12)
- Secondary leukaemias after etoposide (1992) (12)
- Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer (2009) (12)
- Increased radiosensitivity by a combination of 9-cis-retinoic acid and interferon-y in breast cancer cells. (1996) (12)
- The relation between saliva estriol levels in pregnancy and infant birth weight (2004) (12)
- Recurrence of genitals warts in pre-HPV vaccine era after laser treatment (2019) (11)
- Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. (1994) (11)
- Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. (1989) (11)
- Current Academic Clinical Trials in Ovarian Cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009 (2010) (11)
- Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. (2021) (11)
- Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. (1997) (11)
- Effects of retinoic acid and gamma-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. (1995) (11)
- The role of polyamines in interferon and retinoic acid mediated synergistic antiproliferative action. (1989) (11)
- ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. (2020) (11)
- Perception of Labial Size and Objective Measurements-Is There a Correlation? A Cross-Sectional Study in a Cohort Not Seeking Labiaplasty. (2020) (11)
- Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. (2011) (11)
- Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO). (2016) (11)
- Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria. (2017) (11)
- Modulation of secretion of human chorionic gonadotropin by biologic response modifiers on term placenta and choriocarcinoma cells. (1989) (11)
- Clinical Impact of RANK Signalling in Ovarian Cancer (2019) (10)
- Impact of nuchal cord on measurement of fetal nuchal translucency thickness (2007) (10)
- ESGO Statement on the Role of CA‐125 Measurement in Follow-Up of Epithelial Ovarian Cancer (2012) (10)
- Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases. (2003) (10)
- Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients. (2000) (10)
- Clinical Relevance of TAp73 and &Dgr;Np73 Protein Expression in Ovarian Cancer: A Series of 83 Cases and Review of the Literature (2011) (10)
- Effect of tension-free vaginal tape operation on urethral closure function. (2006) (10)
- Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer. (1998) (10)
- Evaluating L1CAM expression in human endometrial cancer using qRT-PCR (2016) (10)
- Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study (2014) (10)
- Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria (2016) (10)
- Marked improvement in the success rate of medical management of early pregnancy failure following the implementation of a novel institutional protocol and treatment guidelines: a follow-up study (2016) (10)
- Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). (2010) (9)
- Prenatal diagnosis of de novo mosaic deletion 13q associated with multiple abnormalities (2002) (9)
- Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge (2016) (9)
- Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer. (2001) (9)
- Evaluation of three mRNA markers for the detection of lymph node metastases. (2006) (9)
- Introduction of organised mammography screening in tyrol: results of a one-year pilot phase (2011) (9)
- Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology: European Society of Gynecological Oncology (ESGO) Statement (2011) (9)
- Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. (1997) (9)
- Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer (2019) (8)
- The importance of stromal tissue in benign prostatic hyperplasia: morphological, immunofluorescence and endocrinological investigations. (1984) (8)
- Increased production of immune activation marker neopterin by colony‐stimulating factors in gynecological cancer patients (1994) (8)
- In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma (1993) (8)
- Treatment of postoperative urinary retention by elongation of tension-free vaginal tape. (2001) (8)
- Platinum or nonplatinum in recurrent ovarian cancer: that is the question. (2017) (8)
- Peritoneal mesothelial cells as a significant source of ascitic immunostimulatory protein 90K. (2000) (8)
- Immune cells in colorectal cancer. (2006) (8)
- Disseminated tumor cells: are they ready for clinical use? (2007) (8)
- AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. (2019) (8)
- Tumor necrosis factor receptor modulator spermatogenesis‐associated protein 2 is a novel predictor of outcome in ovarian cancer (2019) (8)
- ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer. (2020) (8)
- Expression of Retinoic Acid Receptors in Non-Neoplastic Epithelial Disorders of the Vulva and Normal Vulvar Skin (2000) (7)
- Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. (2021) (7)
- Cellular retinoic acid binding protein (CRABP) in retinoblastoma. (1987) (7)
- Suppressive Effects of Neopterin on Inducible Nitric Oxide Synthase Gene Expression in Ovarian Carcinoma Cells in vitro (2001) (7)
- Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1. (2017) (7)
- TNFα signalling predicts poor prognosis of patients with endometrial cancer. (2020) (7)
- L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer (2017) (7)
- Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO—a focus on surgical aspects (2019) (7)
- Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20. (1987) (7)
- [The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma]. (1989) (7)
- Follicle stimulating hormone (FSH) as a surrogate parameter for the effectiveness of endocrine therapy with or without zoledronic acid in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. (2014) (7)
- Peanut agglutinin inhibits proliferation of cultured breast cancer cells. (1988) (7)
- AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS) (2017) (7)
- CA 125 in human milk and serum. (1989) (7)
- Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. (1994) (7)
- Correlation of oestriol levels in saliva, plasma and urine of pregnant women. (1985) (7)
- Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix. (1999) (6)
- Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT (2020) (6)
- NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer (2019) (6)
- Pulsatile versus continuous estradiol exposure in inducing proliferation of cultured ZR-75.1 human breast cancer cells. (1985) (6)
- A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). (2014) (6)
- Getting the Whole Picture: Adding Patient‐reported Outcomes to Adjuvant Endocrine Treatment Evaluation in Premenopausal Breast Cancer Patients (2014) (6)
- Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6) (2022) (6)
- Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum‐response (2018) (6)
- Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR). (2012) (6)
- Relationship between quantity of silver stained nucleolar organizer region associated proteins (Ag-NORs) and growth rate suppression of breast cancer cell lines after interferon-gamma and 4-hydroxy-tamoxifen treatment (1993) (6)
- Joint ENGOT and GOG Foundation requirements for trials with industry partners (2019) (6)
- Evaluation of Vav3.1 as prognostic marker in endometrial cancer (2018) (6)
- Distribution of CA 125 in Placental Tissues (1989) (6)
- Is neoadjuvant chemotherapy in ovarian cancer an excuse for insufficient surgery? (2011) (5)
- Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study (2016) (5)
- Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer (2016) (5)
- [Ultrasound morphologic evaluation of the postmenopausal endometrium. A prospective study]. (1996) (5)
- Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement (2015) (5)
- Effects of adjustable dynamic bedroom lighting in a maternity ward (2019) (5)
- RADIOACTIVITY IN BREAST MILK AFTER CHERNOBYL (1986) (5)
- [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker]. (1995) (5)
- Human interferon-gamma increases adhesion of cultured carcinoma cells to the substratum. (1987) (5)
- The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial. (2009) (5)
- stem cells is a hallmark of cancer Age-dependent DNA methylation of genes that are suppressed in Material Supplemental (2010) (4)
- Activated p38-MAPK and gemcitabine sensitivity in recurrent ovarian cancer. (2008) (4)
- Modulation of ovarian carcinoma OV632 antigen by interferons. (1992) (4)
- Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases (2004) (4)
- AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial. (2022) (4)
- SIGNIFICANCE OF URINARY NEOPTERIN IN GYNECOLOGY AND OBSTETRICS: ONCOLOGY, PREGNANCY, AMNIOTIC FLUID (1982) (4)
- High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing (2015) (4)
- UNCOMMON LOCATION OF PERSISTENT ECTOPIC PREGNANCY FOLLOWING LAPAROSCOPIC SURGERY (1994) (4)
- Joint ENGOT and GOG Foundation requirements for trials with industry partners. (2019) (4)
- Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey (2020) (4)
- Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory (2018) (4)
- High concentration of retinoic acid binding protein in a retinoblastoma. (1985) (4)
- Influence of steroids and retinoic acid on peanut-lectin binding of human breast cancer cells. (1986) (4)
- 941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER. (2014) (4)
- Effects of sex- and glucocorticoid steroids on breast cancer cells grown as either multicellular tumor spheroids or monolayers (1996) (4)
- Antiproliferative effect of hu-interferon-gamma in 674V and J82 bladder carcinoma cell lines (2004) (4)
- CD44 splice variant expression in normal and malignant uterine cervical epithelium. (1998) (4)
- Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer (2020) (3)
- Metabolism of E1 and E2 in Ishikawa endometrium carcinoma cells: Influence of TNFα (1991) (3)
- Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial (2019) (3)
- Spontaneous Isolated Midtrimester Fracture of Tibia and Fibula in a Normal Fetus with in utero Healing and Good Long-Term Outcome (2010) (3)
- Carboplatin and Nonpegylated Liposomal Doxorubicin in Primary Advanced or Recurrent Endometrial Cancer: A Phase 2 Trial Conducted by AGO Austria (2015) (3)
- [Urodynamic parameters before and following a vaginal incontinence operation]. (1986) (3)
- [Lead content of breast milk in heavy traffic and light traffic areas of Tyrol]. (1988) (3)
- European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma (2021) (3)
- Prognostisch relevante Faktoren beim malignen Müllerschen Mischtumor (1990) (3)
- Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview (2010) (3)
- Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report (2011) (3)
- Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies--a randomised Austrian AGO trial. (2008) (3)
- Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. (2011) (3)
- Pregnancy, Delivery and Postpartum Care of Women with Ventriculo-Peritoneal Shunted Hydrocephalus: a case series (2009) (3)
- Effects of Human Recombinant «2arg-lnterferon and 7-lnterferon on Human Breast Cancer Cell Lines: Dissociation of Antiproliferative Activity and Induction of HLA-DR Antigen Expression1 (2006) (3)
- Calcium antagonists for uterine relaxation. (1989) (3)
- Primary operation in synchroneous metastasized invasive breast cancer patients: First oncologic outcomes of the prospective randomized phase III ABCSG 28 POSYTIVE trial. (2017) (3)
- Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. (2012) (3)
- Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer (2010) (3)
- Steroid hormone receptors and prognosis in breast cancer (1988) (3)
- Quality of life and symptoms in longterm survivors with ovarian cancer: It's still an issue. Expression VI - Carolin meets HANNA - holistic analysis of long-term survival with ovarian cancer: The international NOGGO, ENGOT and GCIG survey. (2018) (3)
- Fallopian tube cancer associated with paraneoplastic dermatomyositis -- asymptomatic multivisceral exacerbated dermatomyositis mimicking recurrent widespread malignant disease: case report. (2008) (3)
- Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. (2015) (3)
- ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial. (2021) (3)
- Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO). (2013) (2)
- Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial. (2010) (2)
- Rapid development of resistance to tumor necrosis factor alpha on Ishikawa human endometrial carcinoma cells. (1990) (2)
- ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer. (2021) (2)
- Axillary Lymph Node Status in Early-Stage Breast Cancer Patients with Sentinel Node Micrometastases (0.2-2 mm) (2013) (2)
- Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue (2005) (2)
- Use of IP chemotherapy in ovarian cancer: the critical questions. (2011) (2)
- Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR). (2010) (2)
- Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21). (2009) (2)
- 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial (2022) (2)
- 186 Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT (2021) (2)
- Sensitivity of Breast and Ovarian Cancer Cells for Interferons (IFNs) and Retinoids (1996) (2)
- Smoking in pregnancy (1999) (2)
- Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: The PaLiDo study, a phase II nonrandomized multicenter study. (2012) (2)
- Post-traumatic Stress Disorder Post Partum The Impact of Birth on the Prevalence of Post-traumatic Stress Disorder ( PTSD ) in Multiparous Women Posttraumatic Stress Disorder post partum (2)
- Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study (2018) (2)
- 403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS. (2014) (2)
- LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034) (2022) (2)
- Enhancement of CA 125 expression by interferon-gamma in ovarian carcinoma xenografts (1991) (2)
- [Prognostically relevant factors in malignant mixed Müllerian tumor]. (1990) (2)
- Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition (2019) (2)
- Do obese women benefit less from adjuvant endocrine therapy with aromatase inhibitors? Preliminary analysis on the association of BMI and aromatase inhibitor plasma levels. (2011) (2)
- Neopterin as a Stimulator of Vascular Endothelial Growth Factor and Erythropoietin Gene Expression in an Ovarian Carcinoma Cell Line (2005) (2)
- Role of Hormonal Therapy in Advanced Stage Endometrial Cancer (2019) (2)
- ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer (2019) (2)
- Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial. (2012) (2)
- [Modification of chorionic carcinoma cells by immunomodulators. Cytokines and chorionic carcinoma cells]. (1995) (2)
- Detection of disseminated tumor cells in bone marrow as an independent prognostic factor in primary ovarian cancer patients. (2012) (2)
- [Effect of interleukin 6 on uterine contractility in the human in vivo]. (1998) (2)
- Endometroid carcinoma developing in endometriosis over the symphysis pubis☆ (2013) (2)
- AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC). (2019) (2)
- EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). (2022) (2)
- Prognostic impact of the humoral immune response against p53 protein in advanced epithelial ovarian cancer (1999) (1)
- Association of a common genetic variant of the IGF1 gene with clinical outcome in patients with HER2-positive breast cancer. (2011) (1)
- 0152: Weekly Docetaxel and Irinotecan in Platinum-Refractory and Resistant Ovarian Cancer: a Phase II Study of the Austrian Ago (2006) (1)
- 9PDPD-1 and PD-L1 expression in ovarian cancer (2016) (1)
- Robot-assisted laparoscopic surgery in gynaecology: First experiences and review of the literature (2002) (1)
- Current academic clinical trials in ovarian cancer : Gynecologic Cancer Intergroup ( GCIG ) and United States National Cancer Institute ( NCI ) clinical trials planning meeting , May , 2009 (2010) (1)
- The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership (2015) (1)
- Pure multivisceral manifestation of paraneoplastic dermatomyositis mimicked highly disseminated recurrent carcinoma of the fallopian tube (2008) (1)
- Effect of Neopterin Derivatives on Mitochondrial Dehydrogenase Activity in Ovarian Carcinoma Cell Lines in Vitro (2006) (1)
- Intra- and post-operative catumaxomab in patients with epithelial ovarian cancer: Two-year efficacy results from a multicenter, single-arm, phase II study. (2011) (1)
- EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress) (2021) (1)
- PARP inhibitors in the treatment of ovarian cancer (2020) (1)
- Primary chemotherapy and maintenance therapy in epithelial ovarian cancer (2008) (1)
- [Heart-specific L-myosin in pregnancy and tocolysis therapy]. (1989) (1)
- 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (1)
- A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort (329) (2022) (1)
- Evaluation of RU-27987 as a ligand to determine the progesterone receptor. (1987) (1)
- Tamoxifen and its metabolites: binding to the estrogen receptor and growth effects on breast cancer cells (1983) (1)
- Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer. (2011) (1)
- 935PDBRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial (2017) (1)
- Influence of atracurium and mivacurium on the proliferation of two human cell lines in vitro (2000) (1)
- Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis. (2013) (1)
- Lectin binding sites in cultured human breast cancer cells (2005) (1)
- Interferon–Gamma supprimiert die Expression des Onkogens HER-2 in Ovarialkarzinomzellen (1992) (1)
- Clinical relevance of Vav3.1 expression in ovarian cancer and involvement in mechanisms causing genuine multi-drug resistance. (2018) (1)
- Endometriehyperplasi - Diagnose og behandling (1999) (1)
- Abstract A191: Augmenting the therapeutic efficacy of oncolytic LCMV-GP pseudotyped vesicular stomatitis virus via modulation of the innate immune system (2016) (1)
- Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: Systematic bias assessment of ovarian cancer treatment effectiveness. (2022) (1)
- Measuring of immunoreactivity of carcinoembryonic antigen (CEA) in colorectal cancer by microdensitometry. (1989) (1)
- [Magnetic resonance tomography in follow-up of hydatidiform mole]. (1992) (1)
- [Photodynamic therapy in patients with recurrent gynecologic cancers]. (1993) (1)
- Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial) (2022) (1)
- 294. Age dependence of estrogen- and progesterone receptor distribution in mammary carcinoma (1982) (1)
- Results of the CARMA study to investigate catumaxomab therapy for ascites related to peritoneal carcinomatosis in clinical practice. (2013) (1)
- [Modulation of hCG synthesis by alpha tumor necrosis factor in JAR choriocarcinoma cells]. (1990) (1)
- Adherence evaluation of endocrine treatment in breast cancer: methodological aspects (2012) (1)
- [Endometrial hyperplasia--diagnosis and treatment]. (1999) (1)
- DNA methylation markers for ovarian cancer (2010) (1)
- EP891 Receptor activator of nuclear factor kappa-B ligand expression predicts ovarian cancer outcome (2019) (1)
- [Comparison of conventional radium and high dose rate afterloading brachytherapy in cervix cancer]. (1991) (1)
- [The evaluation of the second-look operation of patients with ovarian carcinoma and tubal carcinoma by means of a retrospective comparison study]. (2002) (1)
- Dubious effects of methadone as an “anticancer” drug on ovarian cancer cell-lines and patient-derived tumor-spheroids (2022) (1)
- [Clinical relevance of reactive thrombocytosis in patients with ovarian cancer]. (1993) (1)
- 8041 POSTER Relevance of Gamma-glutamyltransferase – a Marker for Apoptotic Balance – in Predicting Tumour Stage and Prognosis in Cervical Cancer (2011) (1)
- [Immune activation in patients with ovarian cancers]. (1990) (1)
- Hair safe study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer patients receiving chemotherapy - A prospective interventional study (2022) (1)
- Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin. (1986) (1)
- 5029 POSTER Early termination of a phase II study of the Austrian AGO: Weekly docetaxel and irinotecan in platinum-refractory and resistant ovarian cancer (2007) (1)
- Calcium and calmodulin antagonism for inhibition of uterine contractions (2004) (1)
- Abstract PO-038: Strong decline of newly diagnosed gynecologic and breast cancers during the COVID-19 pandemic: A retrospective analysis from Innsbruck, Austria (2020) (1)
- Evolving strategies to overcome endocrine resistance in breast cancer (2012) (1)
- TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial (2019) (1)
- QUALITY OF THE SURGICAL TREATMENT IN OVARIAN CANCER PATIENTS IN AUSTRIA (2003) (1)
- EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer (2021) (1)
- Breast Cancer : Targets and Therapy Role of pertuzumab in the treatment of HER 2-positive breast cancer (2012) (1)
- Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data. (2012) (1)
- Platinum-resistant ovarian cancer: Prematurely stopped phase II Austrian AGO chemotherapy studies (2012) (0)
- Characteristics of long-term survivors with ovarian cancer: Expression VI-Carolin meets HANNA – the international NOGGO, ENGOT and GCIG survey (2018) (0)
- P294 What is the key issue to evaluate adherence to endocrine treatment in breast cancer patients? Methodological results of a prospective study: Patient-reported outcomes in breast cancer patients undergoing endocrine therapy (PRO-BETh) (2011) (0)
- 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer (2020) (0)
- Regulation of immunostimulating tumor-associated antigen-90K in ovarian cancer cells (1994) (0)
- Abstract P5-11-10: Gonadotropins Plasma Levels Are Significantly Influenced by Body Mass Index in Postmenopausal Breast Cancer Patients Undergoing Endocrine Therapy with Aromatase Inhibitors: Is This a Surrogate Marker for Serum Estrogen Bioactivity? (2010) (0)
- Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer (2018) (0)
- 2022-RA-712-ESGO Real-world prevalence of microsatellite instability testing and related status in patients with recurrent or advanced endometrial cancer initiating first line of therapy in Europe (2022) (0)
- Abstract B114: Innate immunity modulators to enhance oncolytic VSV-GP for the treatment of ovarian cancer (2016) (0)
- P132 Significance of locus-specific TP53 mutations in ovarian cancer (2019) (0)
- Blood Dissemination of Mammaglobin‐Specific RNA During Core Needle Biopsy in Patients with Invasive Breast Carcinoma (2004) (0)
- Assessing Type and Impact of Biases Potentially Occurring when Analyzing Real World Evidence: The Case of Second Line Treatment for Ovarian Cancer (2018) (0)
- Receptor for interferon-gamma, retinol, retinoic acid and steroids in mammary carcinoma (1988) (0)
- How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO). (2012) (0)
- in patients with anemia of chronic disease Dysregulated monocyte iron homeostasis and erythropoietin formation (2013) (0)
- 405 Real-life response to standard of care in advanced ovarian cancer – an observational multi-national cohort study (RESPONSE) (2020) (0)
- Determination of light-chain myosin in pregnancy and under tocolysis (1989) (0)
- Contents, Vol. 35, Supplement 1, 1995 (1995) (0)
- Reply to: A possible chemotherapeutic response by paclitaxel and other antineoplastic agents in treatment of choriocarcinoma in vitro (1996) (0)
- Sachregister Vol. 42, 2002 (2002) (0)
- EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer (2021) (0)
- Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data (2021) (0)
- Occult Metastatic Cells in Breast Cancer Patients (2006) (0)
- Abstract 947: Effects of methadone on ovarian cancer cell-lines and patient-derived tumor-spheroids (2021) (0)
- [Role of the immune parameter neopterin in adnexitis]. (1996) (0)
- Contents, Vol. 22, Supplement 1, 1982 (1982) (0)
- Interleukin-12 heterodimer in the ascitic fluid of patients with ovarian cancer. (1999) (0)
- 00054 CLINICAL RELEVANCE OF DOMINANT-NEGATIVE P73 ISOFORMS FOR RESPONSIVENESS TO CHEMOTHERAPY AND SURVIVAL IN OVARIAN CANCER - EVIDENCE FOR A CRUCIAL P53-P73 CROSS-TALK IN VIVO (2005) (0)
- [Increased spontaneous uterine activity caused by the anti-gestagen ZK 98.299]. (1989) (0)
- [Immunostimulating protein 90K in ovarian carcinoma]. (1996) (0)
- [Biochemical prognostic factors in oncology]. (1993) (0)
- 7-Interferon Reduces Expression of the Protooncogene c-erbB-2 in Human Ovarian Carcinoma Cells (2006) (0)
- 1524P Epidemiology and demography of gynecological sarcoma: Results of the prospective intergroup registry for gynecological sarcoma REGSA (NOGGO RU1) (2022) (0)
- 00040 HIGHER RATE OF THROMBOSIS IN ERYTHROPOIETIN ß TWICE WEEKLY VERSUS STANDARD THERAPY IN PATIENTS WITH GYNECOLOGIC MALIGNANCY: AN AUSTRIAN AGO TRIAL (2005) (0)
- Ovarian cancer stem cells Minireview** (2012) (0)
- Regulation of the EGFR-E2F3a axis by the interferon regulatory factor (IRFs) and by promoter methylation of miR-34a in ovarian cancer. (2016) (0)
- Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1) (2023) (0)
- [Therapy and after care of patients with ovarian cancer]. (1990) (0)
- [Interaction of interferon with retinoic acid]. (1994) (0)
- Editorial Board / Contents / Imprint (2016) (0)
- Synergistic action of interferon-γ and retinoic acid on breast cancer cells (1987) (0)
- First safety results of an international phase II study evaluating oral vinorelbine as a single agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial). (2014) (0)
- Effects of interferon-gamma (IFN-γ), tumor necrosis factor (TNF) and retinoids on established mammary carcinoma cell lines (1987) (0)
- Evaluation of bone marrow: Prediction of outcome and response (2003) (0)
- 745 The clinical impact of MSI and dMMR in advanced endometrial cancer: the effect of online education on clinician knowledge, competence and confidence (2021) (0)
- Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers (2016) (0)
- 2022-RA-1267-ESGO A randomised clinical Trial Investigating olaparib, durvalumab and an anticancer vaccine, UV1 as maintenance therapy in patients with recurrent ovarian cancer. ENGOT-OV56-NSGO-CTU-DOVACC (2022) (0)
- Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress). (2021) (0)
- [Surgical standards in endometrial carcinoma]. (1995) (0)
- Contents, Vol. 29, Supplement 2, 1989 (1989) (0)
- Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study (2006) (0)
- BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer (2018) (0)
- Clinical relevance of a novel EGF pathway directly linked to E2F3a in ovarian cancer (2008) (0)
- ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer (2020) (0)
- 323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer (2020) (0)
- Editorial Board / Contents / Imprint / Contents of Forthcoming Issues (2016) (0)
- Editorial Board / Contents / Imprint (2017) (0)
- [The value of nuclear magnetic resonance tomography in diagnosing invasive trophoblast disease]. (1992) (0)
- Measurement of human chorionic gonadotropin and its free subunits under physiological and pathological conditions (1988) (0)
- Pharma News / Pharma Ticker (2008) (0)
- Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance (2015) (0)
- 2022-RA-702-ESGO Real-world treatment patterns and outcomes in recurrent or advanced endometrial cancer patients initiating 1st-line systemic therapy in Europe: a retrospective chart review study (2022) (0)
- Treg and Teff in the bone marrow of early-stage breast cancer patients with disseminated tumor cells. (2010) (0)
- RECIST/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma (2021) (0)
- [Prognostic significance of tumor markers in cervix cancer]. (1992) (0)
- Abstract P4-02-04: Impact of CYP2D6 Genotype and Side-Effects on Adherence Rates to Tamoxifen in Premenopausal Breast Cancer Patients (2010) (0)
- The effect of retinoic acid on human mammary carcinoma cells in vitro (1985) (0)
- Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. (2023) (0)
- Contents, Vol. 28, Supplement 2, 1988 (1988) (0)
- Editorial Board / Contents / Imprint (2018) (0)
- Feasibility and toxicity of intraperitoneal cisplatin-paclitaxel chemotherapy (IPC) for epithelial ovarian cancer (EOC) in a routine clinical setting (2008) (0)
- Editorial Board / Contents / Imprint (2017) (0)
- Immunotherapy: A New Strategy for the Treatment of Cervical Cancer. Interview with Dr. Christian Marth and Dr. Sharad Ghamande (2018) (0)
- DNA Methylation Profiles in Cancer Cells and Tumor Stroma: Association with HER-2/neu Status in Primary Breast Cancer. (2006) (0)
- Case 1 – Long-term response to bevacizumab and paclitaxel as second-line therapy in metastatic vaginal carcinoma (2016) (0)
- P12 Methylated DNA on tampons to detect endometrial and cervical cancer (2004) (0)
- Editorial Board / Contents / Imprint (2018) (0)
- Automated quantitative evaluation of immunohistochemical thyroblobulin content in sections of differentiated thyroid carcinomas (1984) (0)
- Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications (2015) (0)
- RASSF1A DNA methylation in bone marrow (mRASSF1ABM) or peripheral blood plasma (mRASSF1APB) of primary breast cancer (BC) patients (2007) (0)
- Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment. (2012) (0)
- [Inhibition of spontaneous uterine contractions by gestagens]. (1989) (0)
- Clinical impact of BRCA1 and BRCA2 mRNA expression in ovarian cancer. (2018) (0)
- [Immunohistochemical detection of progesterone receptors in primary breast cancer and lymph node metastases]. (1993) (0)
- The role of disseminated and circulating tumour cells in breast cancer (2006) (0)
- Editorial Board / Contents / Imprint (2018) (0)
- [Adjuvant therapy of breast cancer with trastuzumab]. (2008) (0)
- OVARIAN PRESERVATION IN THE SURGICAL TREATMENT OF CERVICAL CARCINOMA (1999) (0)
- MSC as carrier cells for a rhabdovirus-based oncolytic virotherapy of ovarian cancer (2014) (0)
- P155 The microRNA 34 family and its clinical significance in ovarian cancer (2019) (0)
- 2022-RA-837-ESGO Characterization of long-term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO/A-AGO (2022) (0)
- Transforming GrowthFactor-f3 Synthesis by HumanPeritoneal Mesothelial Cells Induction byInterleukin- 1 (1996) (0)
- [Thyroid gland cancer of the ovary]. (1990) (0)
- Effects of retinoic acid and 4-OH tamoxifen on human breast cancer cells in vitro (1984) (0)
- P139 The role of transcriptomic SMARCA4 expression in ovarian cancer biology (2019) (0)
- How to assess response to immune therapy (2016) (0)
- Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort (2020) (0)
- [Inhibition of spontaneous uterine contractions by magnesium. Magnesium tocolysis]. (1990) (0)
- CDK12/13 inhibition in ovarian cancer cell lines (2023) (0)
- Editorial Board / Contents / Imprint (2017) (0)
- Phenotypic alteration of leukemic hairy cells upon interferon-alpha treatment in vitro (1986) (0)
- INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line (2023) (0)
- Immunologically relevant markers in ovarian cancer (1994) (0)
- PATH – Patients Tumorbank of Hope (2008) (0)
- Contents, Vol. 31, Supplement 2, 1991 (1991) (0)
- Editorial Board / Contents / Imprint (2018) (0)
- 70P PAI 1 IN HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER (2009) (0)
- Contents Vol. 24, 2008 (2008) (0)
- [Ovarian cancer cells and interferon: aspects of a biological network]. (1988) (0)
- HIGH INTERFERON-GAMMA EXPRESSION IS ASSOCIATED WITH GOOD PROGNOSIS IN OVARIAN CANCER (2004) (0)
- Consensus Recommendations on Methodical Aspects and Clinical Relevance of the Evidence of Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer (2007) (0)
- Denosumab in the Treatment of Breast Cancer Patients with Bone Metastasis (2016) (0)
- Latest progress in treatment of gynaecological cancers (2008) (0)
- Neoadjuvant Chemotherapy Cannot Be Regarded as Adequate Routine Therapy Strategy of Advanced Ovarian Cancer (2011) (0)
- Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA 125 – a Prospective Cohort Trial (2021) (0)
- P223 Oncologic outcome of areola-sparing mastectomy with immediate reconstruction using free flap techniques compared with conventional skin-sparing mastectomy (2011) (0)
- Neoadjuvant treatment of HER2 positive breast cancer with concomitant nonpegylated liposomal doxorubicin (NPLD), docetaxel and dual blockade with trastuzumab and pertuzumab: A retrospective analysis of pCR and cardiac safety. (2017) (0)
- Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer (2016) (0)
- 00016 PEGYLATED LIPOSOMAL DOXORUBICIN AND GEMCITA-BINE IN PLATINUM-REFRACTORY AND RESISTANT OVARIAN CANCER FOLLOWING PLATINUM-TAXANE THERAPY-A PHASE II STUDY OF THE AUSTRIAN AGO (2005) (0)
- 2022-RA-1074-ESGO AGO-OVAR 2.29 (ENGOT-ov34): atezolizumab in combination with bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer (2022) (0)
- Editorial Board / Contents / Imprint (2017) (0)
- 17 (1989) 461 Determination of light-chain myosin in pregnancy and under toco- lysis (1989) (0)
- EP1004 Prognostic impact of BRCA2 mRNA expression in ovarian cancer: validation using the TCGA cohort (2019) (0)
- The Impact of COVID-19 Pandemic on Gynecological and Breast Cancer Detection Rate: A Tertiary Center Perspective. (2021) (0)
- Contents, Vol. 25, Supplement 2, 1985 (1985) (0)
- Activated cellular immunity in ovarian carcinoma patients. (1994) (0)
- Contents, Vol. 34, Supplement 1, 1994 (1994) (0)
- Contents Vol. 55, 2009 (2009) (0)
- Subject Index Vol. 24, 2008 (2008) (0)
- 0156 Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial (2009) (0)
- Longterm survival benefit of neoadjuvant liposomal doxorubicin, docetaxel, and trastuzumab in HER2-overexpressing breast cancer: A retrospective and multicenter analysis. (2018) (0)
- INTERFERON-GAMMA IN COMBINATION WITH CARBO- PLATIN AND PACLITAXEL AS A SAFE AND EFFECTIVE FIRST-LINE TREATMENT FOR ADVANCED OVARIAN CANCER: RESULTS OF A PHASE (2004) (0)
- Contents, Vol. 34, Supplement 1, 1994 (1994) (0)
- Managing relapsed ovarian cancer in a rapidly evolving landscape. (2017) (0)
- Treatment of malignant ascites with catumaxomab in clinical practice: Results of an observational trial (2013) (0)
- An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer. (2023) (0)
- Contents, Vol. 33, Supplement 1, 1993 (1993) (0)
- Randomized comparison of neoadjuvant docetaxel (D), epirubicin (E) and pegfilgrastim (P) (+ trastuzumab [T] in HER2+ patients [pts]) with and without capecitabine (C) for operable breast cancer (BC): Results of a planned safety analysis of ABCSG 24 (2007) (0)
- Prognostic relevance of supradiaphragmatic lymph nodes in advanced stage ovarian cancer. (2018) (0)
- THE IMPACT OF BRACHYTHERAPY ON SURVIVAL IN CERVICAL CANCER (2003) (0)
- Editorial Board / Contents / Imprint (2016) (0)
- [Endocrinologic studies in anorexia nervosa in controlled caloric intake]. (1988) (0)
- Endocrine Therapy – What Else? (2008) (0)
- A comparison of four technologies for detecting p53 aggregates in ovarian cancer (2022) (0)
- Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer (2022) (0)
- Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting (2010) (0)
- [Inhibition of uterine contractions by alpha adrenergic receptor blockaders]. (1987) (0)
- Synergistic interaction of retinoids and interferons in breast cancer (1997) (0)
- Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer (2014) (0)
- Contents, Vol. 30, Supplement 1, 1990 (1990) (0)
- 3P NaPi2b expression in high grade serous ovarian cancer: Results from combined data sets (2023) (0)
- [Combination therapy of Buschke-Löwenstein tumor with CO2 laser and interferon-alpha]. (1992) (0)
- 713 Palbociclib and metformin show anticancer efficacy in high grade serous ovarian cancer (2021) (0)
- Editorial Board / Contents / Imprint (2017) (0)
- Epidermal growth factor-mediated signaling in ovarian cancer and the role of miR-34a and 6p22 gene amplification-based E2F3a control. (2011) (0)
- Optimizing the dose of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC): A posthoc analysis of a phase 1b expansion study in ovarian cancer (319) (2022) (0)
- [Modification of hCG secretion by biological modulators of cell response and cytostatics in the normal placenta and choriocarcinoma cells]. (1988) (0)
- The Biologically Active Concentrations of Antiestrogens Are Disproportionately Elevated Relative to the Binding Affinity for the Estrogen Receptor (1986) (0)
- Consensus Statements for the Detection and Clinical Implementation of Disseminated Tumor Cells in Bone Marrow of Primary Breast Cancer Patients (2006) (0)
- [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer]. (1993) (0)
- Comparative Effectiveness Analysis Using Real World Evidence (RWE) and Applying a Causal Marginal Structural Model: the Case of Second-Line Treatment in Patients with Ovarian Cancer (2018) (0)
- PARITY AS PROGNOSTIC FACTOR FOR MALIGNANT MIXED MÜLLERIAN TUMOURS (1989) (0)
- 439 Primary symptoms in women with different histopathological subtypes of gynaecological sarcoma – results of a prospective intergroup registry for gynaecological sarcoma (REGSA – NOGGO RU1) (2020) (0)
- Hair Safe Study: Effects of scalp cooling on hair preservation and hair regrowth in breast cancer therapy—A prospective interventional study. (2022) (0)
- 2022-RA-909-ESGO AGO-OVAR 28/ENGOT-ov57: niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (a multicentre randomised phase III trial) (2022) (0)
- Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial (2017) (0)
- Meeting and Conferences (2008) (0)
- Editorial Board / Contents / Imprint (2018) (0)
- 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer (2021) (0)
- TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer (2022) (0)
- Myoblobin ― A new approach to cardiotoxicity of cancerostatic agents (1989) (0)
- Contents, Vol. 32, Supplement 1, 1992 (1992) (0)
- [Doppler ultrasound of the endometrium during hormone replacement]. (1995) (0)
- Abstract P4-14-11: Efficacy and cardiac safety in neoadjuvant treatment of Her2 positive breast cancer with concomitant nonpegylated liposomal doxorubicin, docetaxel and dual blockade with trastuzumab and pertuzumab: A retrospective analysis (2016) (0)
- 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (2022) (0)
- Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Sw (2018) (0)
- Presence of bone marrow micrometastasis predicts metastatic pattern and disease-free interval in breast cancer patients – results from the Collaborative Group Bone Marrow Micrometastasis (2008) (0)
- Interaktion von Interferon mit Vitamin-A-Säure (1994) (0)
- Contents, Vol. 32, Supplement 1, 1992 (1992) (0)
- Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial (2022) (0)
- Effects of retinoids, interferon gamma and TNF alpha on human breast and ovarian cancer cells (1990) (0)
- 8 Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC) (2010) (0)
- Prognostic significance of urinary neopterin in ovarian cancer a study of the Austrian Gynecologic Oncology Group. (2014) (0)
- Contents, Vol. 27, Supplement 2, 1987 (1987) (0)
- The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007) (2008) (0)
- Subject Index Vol. 55, 2009 (2009) (0)
- Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2– breast cancer: subgroup analysis of STEPAUT (2017) (0)
- cell activity in various disease states Human large granular lymphocytes and their relationship to natural killer (2011) (0)
- UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585) (2022) (0)
- [The value of tumor markers in vulvar cancer]. (1992) (0)
- Effects of biological response modifiers and cytotoxic drugs on the hCG secretion of term placental and choriocarcinoma cells (1988) (0)
- 39MO Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer (2023) (0)
- Treatment patterns and outcomes among patients with recurrent or advanced endometrial cancer in Europe: Endometrial Cancer Health Outcomes Europe (ECHO EU) Study. (2022) (0)
- The European Network of Gynecological Oncological Trial Groups (2012) (0)
- Retinoic acid- and retinol binding proteins in melanomas and retinoblastomas. (1987) (0)
- P31 DNA methylation profiles in breast cancer — relation to hormone receptors and role in response to adjuvant endocrine treatment (2004) (0)
- [On the problem of the cardiotoxicity of epirubicin-cisplatin]. (1988) (0)
- Abstract PD08-02: The Impact of Patient Reported Outcomes (PRO) on the Evaluation of Therapy Related Side-Effects and the Improvement of Adherence to Endocrine Treatment in Breast Cancer Patients (2010) (0)
- [Interferon-gamma suppresses expression of the HER-2 oncogene in ovarian cancer cells]. (1992) (0)
- Abstract P6-08-23: Serum–based test to identify patients with early relapse treated with adjuvant hormonal therapy (2015) (0)
- LONGTERM EFFECT OF COLPORRHAPHY REGARDING PROLAPSE, URINARY INCONTINENCE AND QUALITY OF LIFE (1999) (0)
- Primary surgery versus no surgery in synchronous metastastic breast cancer: Patient-reported outcomes of the ABCSG 28 Posytive trial. (2017) (0)
- The role of gamma-glutamyltransferase in malignant transformation and prognosis of ovarian cancer. (2013) (0)
- THE CLINICAL SIGNIFICANCE OF NEOPTERIN SAMPLING IN THE FOLLOWUP OF PATIENTS WITH GENITAL CANCER (1983) (0)
- [Modification of the EGF receptor by cytostatic treatment]. (1991) (0)
- Proliferation of two human cell-lines in vitro under the influence of cisatracurium with and without carboxyl esterase: 5 (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Christiane Marth?
Christiane Marth is affiliated with the following schools:
